Changchun BCHT Biotechnology Co with strategic investment from SDIC Fund Management was listed on SSE Star Market on June 25, 2021. Coded688276.SH, the stock recorded a 226 per cent rise, from its issuing price of 36.35 yuan per share to a rocketing 118.50 yuan per share at the closing time of the day.

SDIC Fund Management has long been focusing its investment in the sector of innovative bio-pharmaceuticals. As a strategic investor, SDIC Fund Management aids Changchun BCHT Biotechnology to invest constantly in research and development, develop new products, new techniques and new technology, and build itself into a R&D-driven pharmaceutical company of disease control and prevention. This has also helped SDIC Fund Management to expand its investment scope in the vaccine industry.

Changchun BCHT Biotechnology is an innovative bio-pharmaceutical company that specializes in prevention and treatment of infectious diseases. At present, the company has three approved vaccines: chickenpox vaccine, rabies vaccine and influenza vaccine. In the meantime, it has 14 vaccines under research and two under-research human monoclonal antibodies for infectious disease control and prevention.

Its chickenpox vaccine takes the lead in sales at the domestic market due to its safety and stability while BCHT Biotechnology is the only pharmaceutical company authorized by WHO to manufacture freeze-dried nasal spray influenza vaccine in China.

Established in 2004, Changchun BCHT Biotechnology Co., is devoted to research and development of vaccines and industrializing their production. By December 31, 2020, the company had 117 researchers and 26 invention patents.